Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2021

Open Access 01.12.2021 | Research article

Impact of hospital volume on clinical outcomes of hospitalized heart failure patients: analysis of a nationwide database including 447,818 patients with heart failure

verfasst von: Hidehiro Kaneko, Hidetaka Itoh, Haruki Yotsumoto, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Kojiro Morita, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Hideo Yasunaga, Issei Komuro

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2021

Abstract

Background

Hospital volume is known to be associated with outcomes of patients requiring complicated medical care. However, the relationship between hospital volume and prognosis of hospitalized patients with heart failure (HF) remains not fully understood. We aimed to clarify the impact of hospital volume on clinical outcomes of hospitalized HF patients using a nationwide inpatient database.

Methods and results

We studied 447,818 hospitalized HF patients who were admitted from January 2010 and discharged until March 2018 included in the Japanese Diagnosis Procedure Combination database. According to the number of patients, patients were categorized into three groups; those treated in low-, medium-, and high-volume centers. The median age was 81 years and 238,192 patients (53%) were men. Patients who had New York Heart Association class IV symptom and requiring inotropic agent within two days were more common in high volume centers than in low volume centers. Respiratory support, hemodialysis, and intra-aortic balloon pumping were more frequently performed in high volume centers. As a result, length of hospital stay was shorter, and in-hospital mortality was lower in high volume centers. Lower in-hospital mortality was associated with higher hospital volume. Multivariable logistic regression analysis fitted with generalized estimating equation indicated that medium-volume group (Odds ratio 0.91, p = 0.035) and high-volume group (Odds ratio 0.86, p = 0.004) had lower in-hospital mortality compared to the low-volume group. Subgroup analysis showed that this association between hospital volume and in-hospital mortality among overall population was seen in all subgroups according to age, presence of chronic renal failure, and New York Heart Association class.

Conclusion

Hospital volume was independently associated with ameliorated clinical outcomes of hospitalized patients with HF.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
DPC
Diagnosis Procedure Combination
HF
Heart failure
ICD-10
International Classification of Disease and Related Health Problems 10th Revision
NYHA
New York Heart Association

Background

Heart failure (HF) is a major cause of unexpected hospitalization in developed countries, and hospitalization due to HF is also a great economic burden [15]. Therefore, providing appropriate acute healthcare services for hospitalized HF patients and building up an optimal medical care system is strongly required. From the perspective of medical care system, hospital volume attracts clinical interest. Previous studies showed that hospital volume was associated with outcomes of not only patients with advanced cardiovascular diseases [69] but also those requiring intensive hospital care [1012]. Taking these into consideration, hospital volume may influence the outcomes of hospitalized patients with HF. Several preceding studies examined the relationship between hospital volume and outcomes in patients with HF [1316]. For example, Kumbhani et al. analyzed the Get With The Guidelines-HF registry including elderly HF patients and showed that hospital volume was marginally associated with outcomes up to 6 months of follow-up [13]. However, most of the research in this field was conducted among patients in North America, and real-world data on the association of hospital volume with outcomes of hospitalized HF patients have been insufficient. In this study, we sought to explore the effect of hospital volume on in-hospital outcomes of patients with HF using a nationwide inpatient database in Japan.

Methods

Study design and data source

The Diagnosis Procedure Combination (DPC) database is a nationwide inpatient database in Japan that includes administrative claims and clinical data for approximately 8 million hospitalized patients per year from more than 1200 participating hospitals including all 82 academic hospitals. The hospitals participating in the DPC database were distributed across all 47 prefectures in Japan. The DPC database represents approximately 50% of all acute inpatients and covers more than 90% of all tertiary-care emergency hospitals in Japan. Academic hospitals are obliged to participate in this database. The participation in this database of community hospitals is voluntary [1720]. The database collates main diagnoses, comorbidities present at admission, and complications during hospitalization using the International Classification of Disease and Related Health Problems 10th Revision (ICD-10) codes.

Definition of hospital volume

We defined hospital volume as the total number of hospitalized patients with HF during the study period at each hospital. We categorized hospitals into tertile (low-, medium-, and high volume) groups, with approximately equal numbers of patients in each group. We divided study patients into three groups by this category.

Statistical procedure

Continuous and categorical data were presented as median (interquartile range) and number (percentages), respectively. We compared continuous data using one-way analysis of variance. We performed chi-square analysis to compare categorical variables. Univariate logistic regression analysis was used to identify the association between each covariate (including hospital volume) and in-hospital mortality. The association of hospital volume with in-hospital mortality was evaluated using a multivariable logistic regression analysis with adjustment for other patient backgrounds, while also adjusting for within-hospital clustering using a generalized estimating equation [21]. We performed subgroup analysis according to age, presence of chronic renal failure, and New York Heart Association class. A probability value of < 0.05 was considered to indicate statistically significant difference. We performed statistical analysis using SPSS version 25 and STATA version 16.

Results

Study population

We studied 466,921 patients aged ≥ 20 years with New York Heart Association (NYHA) class ≥ II, admitted and discharged between January 2010 and March 2018 with the main discharge diagnosis of HF defined by ICD-10 codes I50.0, I50.1, and I50.9. Exclusion criteria were as follows: (1) length of hospital stay ≤ 2 days (n = 15,270) and (2) major procedures under general anesthesia (n = 3833). The final number of enrolled patients analyzed was 447,818.

Baseline clinical characteristics

Table 1 presents the distribution of the numbers of the patients. We categorized centers into the following three groups according to the volume of hospitals where patients were admitted: low (number of patients < 598), medium (598–1009 patients), and high (> 1009). Median age was 81 years, and there was a statistical difference in the percentage of patients aged ≥ 85 years between three groups (p < 0.001). The proportion of patients having NYHA class IV symptom was 30.2% in low volume center, 32.5% in medium volume centers, and 35.5% in high volume center. There was a statistical significant difference in the proportion of patients having NYHA class IV symptom (p < 0.001). The proportion of intravenous use of inotropic agent, nitrate, and furosemide increased with hospital volume category.
Table 1
Characteristics of study population
 
Hospital volume
 
Low (n = 149,182)
Medium (n = 149,507)
High (n = 149,129)
p value
Number of hospital
648
190
107
 
Number of patients in each hospital
400 (276–504)
810 (692–919)
1405 (1158–1634)
 
Age (years)
81 (72–87)
81 (72–87)
80 (71–86)
< 0.001
Age ≥ 85 years
53,068 (35.6)
51,603 (34.5)
48,549 (32.6)
< 0.001
Male sex
78,205 (52.4)
79,548 (53.2)
80,439 (53.9)
< 0.001
Body mass index (kg/m2)
22.1 (19.6–25.0)
22.2 (19.6–25.0)
22.0 (19.5–24.8)
< 0.001
Hypertension
96,539 (64.7)
102,989 (68.9)
101,547 (68.1)
< 0.001
Diabetes mellitus
45,518 (30.5)
48,361 (32.3)
47,140 (31.6)
< 0.001
Chronic renal failure
20,996 (14.1)
22,222 (14.9)
22,285 (14.9)
< 0.001
Chronic liver disease
6086 (4.1)
6185 (4.1)
5246 (3.5)
< 0.001
Chronic respiratory disease
17,282 (11.6)
17,707 (11.8)
15,752 (10.6)
< 0.001
Smoking
43,317 (29.0)
48,219 (32.3)
52,262 (35.0)
< 0.001
Myocardial infarction
3,699 (2.5)
4,182 (2.8)
4,636 (3.1)
< 0.001
Dilated cardiomyopathy
10,853 (7.3)
11,463 (7.7)
11,810 (7.9)
< 0.001
Ventricular tachycardia/ventricular fibrillation
5,751 (3.9)
6,664 (4.5)
7,874 (5.3)
< 0.001
Shock
2,918 (2.0)
3,167 (2.1)
2,680 (1.8)
< 0.001
Anemia
21,466 (14.4)
24,775 (16.6)
25,373 (17.0)
< 0.001
Barthel Index
65 (15–100)
65 (15–100)
55 (5–100)
< 0.001
New York Heart Association
   
< 0.001
Class II
46,002 (30.8)
43,519 (29.1)
40,294 (27.0)
 
Class III
58,106 (38.9)
57,366 (38.4)
55,967 (37.5)
 
Class IV
45,074 (30.2)
48,622 (32.5)
52,868 (35.5)
 
Medications within two days after admission
    
Beta blocker
44,322 (29.7)
48,517 (32.5)
55,547 (37.2)
< 0.001
Renin-angiotensin system inhibitor
50,814 (34.1)
53,377 (35.7)
62,167 (41.7)
< 0.001
Angiotensin converting enzyme inhibitor
21,565 (14.5)
23,160 (15.5)
26,987 (18.1)
< 0.001
Angiotensin II receptor blocker
30,206 (20.2)
31,180 (20.9)
36,480 (24.5)
< 0.001
Mineralocorticoid receptor antagonist
44,609 (29.9)
47,290 (31.6)
53,716 (36.0)
< 0.001
Intravenous inotropic agent
24,788 (16.6)
25,138 (16.8)
28,310 (19.0)
< 0.001
Intravenous nitrate
26,825 (18.0)
31,741 (21.2)
34,999 (23.5)
< 0.001
Intravenous furosemide
97,917 (65.6)
101,240 (67.7)
105,515 (70.8)
< 0.001
Data are expressed as median (interquartile range) or number (percentage)

Procedures during hospitalization

Table 2 summarized procedures and outcomes during hospitalization. There were statistically significant differences in the proportion of patients requiring respiratory support, hemodialysis, and intra-aortic balloon pumping, medical cost, lengths of hospital stay, and in-hospital mortality (all, p < 0.001). The proportion of patients requiring respiratory support and intra-aortic balloon pumping increased with hospital volume category. Medical cost increased, whereas length of hospital stay was reduced with hospital volume. Finally, in-hospital mortality decreased with hospital volume.
Table 2
Procedures and clinical outcomes during hospitalization
 
Hospital volume
 
Low (n = 149,182)
Medium (n = 149,507)
High (n = 149,129)
p value
Respiratory support
19,689 (13.2)
23,151 (15.5)
27,814 (18.7)
< 0.001
Hemodialysis
3594 (2.4)
3909 (2.6)
3882 (2.6)
< 0.001
Intra-aortic balloon pumping
916 (0.6)
1073 (0.7)
1186 (0.8)
< 0.001
Extra-corporeal membrane oxygenation
132 (0.1)
160 (0.1)
158 (0.1)
0.200
Cost (JPY)
712,555 (474,773–1,144,035)
743,775 (504,863–1,165,348)
755,800 (519,243–1,181,185)
< 0.001
Cost (USD)
6556 (4368–10,525)
6843 (4645–10,721)
6953 (4777–10,867)
< 0.001
Length of hospital stay (days)
18 (11–29)
17 (11–28)
16 (11–25)
< 0.001
In-hospital death
11,068 (7.4)
10,067 (6.7)
9687 (6.5)
< 0.001
Data are expressed as median (interquartile range) or number (percentage)

Impact of hospital volume on in-hospital mortality

Table 3 showed the result of the logistic regression analyses. Univariate logistic regression analysis showed that medium-volume group (Odds ratio 0.90, p < 0.001) and high-volume group (Odds ratio 0.87, p < 0.001) had lower in-hospital mortality compared to the low-volume group. The multivariable logistic regression analysis fitted with a generalized estimating equation for in-hospital mortality also showed that medium-volume group (Odds ratio 0.91, p = 0.035) and high-volume group (Odds ratio 0.86, p = 0.004) had lower in-hospital mortality compared to the low-volume group.
Table 3
Determinants of in-hospital death
 
Univariate logistic regression analysis
Multivariable logistic regression fitted with generalized estimating equation
Odds ratio
95% Confidence interval
p value
Odds ratio
95% Confidence interval
p value
Hospital volume
      
Low
Reference
  
Reference
  
Medium
0.90
0.88–0.93
< 0.001
0.91
0.83–0.99
0.035
High
0.87
0.84–0.89
< 0.001
0.86
0.78–0.95
0.004
Age (years)
1.05
1.05–1.06
< 0.001
1.04
1.04–1.04
< 0.001
Sex
      
Female
Reference
  
Reference
  
Male
0.86
0.84–0.88
< 0.001
1.27
1.23–1.32
< 0.001
Body mass index (kg/m2)
0.90
0.90–0.90
< 0.001
0.95
0.95–0.96
< 0.001
Hypertension
0.43
0.42–0.44
< 0.001
0.53
0.50–0.55
< 0.001
Diabetes mellitus
0.78
0.76–0.80
< 0.001
1.03
0.99–1.06
0.120
Chronic renal failure
1.71
1.66–1.75
< 0.001
1.57
1.51–1.63
< 0.001
Chronic liver disease
1.33
1.26–1.40
< 0.001
1.45
1.36–1.55
< 0.001
Chronic respiratory disease
1.01
0.98–1.05
0.568
0.98
0.94–1.03
0.473
Myocardial infarction
1.93
1.83–2.04
< 0.001
1.46
1.35–1.57
< 0.001
Dilated cardiomyopathy
0.87
0.83–0.91
< 0.001
1.19
1.13–1.26
< 0.001
Smoking
0.68
0.66–0.69
< 0.001
0.88
0.85–0.92
< 0.001
New York Heart Association
      
Class II
Reference
  
Reference
  
Class III
1.92
1.85–1.99
< 0.001
1.68
1.58–1.79
< 0.001
Class IV
4.49
4.33–4.66
< 0.001
3.36
3.11–3.63
< 0.001
Ventricular tachycardia/ventricular fibrillation
1.77
1.69–1.85
< 0.001
1.97
1.83–2.11
< 0.001
Shock
5.76
5.49–6.04
< 0.001
3.20
2.85–3.60
< 0.001
Anemia
1.55
1.50–1.59
< 0.001
1.35
1.30–1.41
< 0.001
Barthel Index per 10
0.84
0.83–0.84
< 0.001
0.89
0.89–0.90
< 0.001
Administration within two days
      
Beta blocker
0.61
0.59–0.63
< 0.001
0.94
0.90–0.97
< 0.001
Renin-angiotensin system inhibitor
0.41
0.40–0.42
< 0.001
0.62
0.60–0.65
< 0.001
Mineralocorticoid receptor antagonist
0.63
0.61–0.65
< 0.001
0.83
0.80–0.86
< 0.001
Intravenous inotropic agent
2.88
2.81–2.95
< 0.001
2.13
2.04–2.23
< 0.001
Intravenous nitrate
0.64
0.62–0.66
< 0.001
0.57
0.54–0.60
< 0.001
Intravenous furosemide
1.32
1.29–1.36
< 0.001
0.97
0.94–1.01
0.172

Subgroup analysis

Figure 1 presents the results of the subgroup analyses. Inverse association between hospital volume and in-hospital mortality was seen in all the subgroups including age (A), presence of chronic renal failure (B), and NYHA class (C).

Discussion

Using a nationwide inpatient database of hospitalized patients with HF, we examined the influence of hospital-volume on clinical outcomes of HF patients. The key findings of the present study are as follows: (1) Patients in higher volume hospitals had more severe condition at admission. (2) Higher volume hospitals provided advanced cardiorespiratory support more aggressively. (3) Patients admitted in high volume hospitals had lower in-hospital mortality compared to those admitted to low volume hospitals even after adjustment for the covariates.
Baseline NYHA class increased with hospital volume, suggesting that patients admitted to higher volume centers were more severe than those admitted to low volume centers. Nevertheless, clinical outcomes were better in high volume centers than in low volume centers in association with early administration of medical agents and aggressive advanced cardiorespiratory supports.
In this study, we performed the multiple logistic regression analysis fitted with generalized estimating equation to identify the determinants of in-hospital death. Results of the multiple logistic regression analysis such as the association of chronic liver disease [2224] and cigarette smoking (so called “smoker’s paradox” [25, 26]) with outcomes were concordant with preceding studies focusing on patients with HF, and our results demonstrated that hospital volume was independently associated with in-hospital mortality among patients hospitalized for HF.
Our findings were concordant with those in previous studies on the association between hospital volume and outcomes of HF patients, which also indicated that higher center volume was associated with lower mortality [14, 16]. On the contrary, the analysis of the Get With The Guidelines-HF registry which was linked to Medicare inpatient data of 342 hospitals showed that hospital volume was marginally associated with chronic phase outcomes, but not associated with in-hospital mortality [13]. Therefore, there has remained a room for further investigations in this field. Moreover, considering that previous studies examined patients limited to specific health insurance or community, our study has several advantages. Japan has a universal health care insurance system and patients are provided with equal health care access with equal fees which the Japanese government set. Further, our database is a nationwide inpatient database which could exclude region specific factors. Therefore, this study has strength in generalizability. Previous studies [14, 16] showed that higher hospital volume was associated with medical costs, and our study showed a similar trend. However, the difference in medical costs between low and high hospital volume hospitals was not so large in this study. Longer hospital stay in low volume hospitals and advanced procedures in high volume centers seemingly offset the difference in medical costs.
Several possible explanations can be suggested for the relationship between hospital volume and clinical outcomes. First, therapeutic management for hospitalized HF patients is complex and complicated. It requires a multidisciplinary team approach including primary care physicians, cardiologists, HF specialists, intensivists, cardiac surgeons, nurses, pharmacists, nutritionists, and physiotherapists who had not only professional training but also a great deal of experience in real-world clinical practice. Health care professionals in high volume centers may be more familiar with advanced treatment for hospitalized patients with HF. Therefore, rich experience in high volume centers may lead to better clinical outcomes. Second, various complications such as hemodynamic collapse, life-threatening arrhythmia, acute kidney injury, multiorgan dysfunction, stroke, and infection can occur during the clinical course of hospitalized patients with HF, and these complications require quick and appropriate management. A previous study reported that high volume centers could provide better management for complications in patients undergoing cardiac surgeries [27]. Therefore, better outcomes in high volume centers may attribute to better management for complications in patients with HF. Third, high volume centers may have more healthcare professional staffs and medical infrastructure. Abundant medical resources can also contribute to favorable outcomes in high volume centers. Finally, it could be also possible that better prognosis of HF patients leads to an increase in the number of patients through referral and results in further increase in hospital volume.
This study has clinical implications. As the prevalence of HF is increasing, nationwide actions for the optimal management of HF are required [28, 29]. From this point of view, establishing medical system for HF is important. The results of the present study suggest the importance of high volume centers for HF treatment. On the other hand, maintaining appropriate hospital access for patients with HF in each geographic region is essential because patients with acute HF requiring hospital admission need accessible hospitals which can provide emergency medical care. Therefore, low volume centers in each area is also indispensable. However, considering that the difference in in-hospital mortality according to hospital volume was seemingly pronounced in patients with severe conditions such as older age, chronic renal failure, and NYHA class IV, primary risk stratification for HF patients is important and we should prepare regional medical system for patients with HF. For example, it may be useful that emergency service or primary physicians determine a hospital where patients are transferred according to estimated severity of patients with HF.
There are several limitations in this study. We performed the multivariable logistic regression analysis to adjust for covariates, but a possibility of residual bias could not be eliminated. Because of the nature of the retrospective design, recorded diagnoses are commonly less well validated. Hospital volume was defined as the total number of hospitalized patients with HF during the study period at each hospital. Although some hospitals could have periods of time when they were not enrolling patients, we did not have enough information to assess this point in detail. Our database lacked data regarding blood pressure, heart rate (tachycardia and bradycardia), arrhythmia, HF etiology, left ventricular ejection fraction, diastolic function, right ventricular function, biomarkers such as brain natriuretic peptide, and other concomitant diseases, which can affect the clinical outcomes of hospitalized HF patients. In addition to these, other many factors are associated with the outcomes of HF patients. For example, serum uric acid level is also known to affect the prognosis of patients with HF [30, 31]. However, data on serum uric acid level were not available in this study. A previous study reported that higher hospital volume was associated with lower 6-month mortality and lower 6-month readmissions in patients with HF [13]. However, the long-term prognosis could not be assessed in this database.

Conclusion

The analysis of a nationwide inpatient database including 447,818 hospitalized HF patients showed better clinical outcomes of HF patients in high volume centers compared to those in low volume centers. We believe that the results of this study are resourceful for preparing medical care system for hospitalized HF patients in the era of increasing prevalence of HF worldwide.

Ethics approval

This study was approved by the Institutional Review Board of The University of Tokyo [3501-(3)]. We conducted this study in accordance with the Declaration of Helsinki. Because of the anonymous nature of this database, the requirement for informed consent was waived.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics C, Stroke Statistics S. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-245. https://doi.org/10.1161/CIR.0b013e31828124ad.CrossRefPubMed Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics C, Stroke Statistics S. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-245. https://​doi.​org/​10.​1161/​CIR.​0b013e31828124ad​.CrossRefPubMed
8.
Zurück zum Zitat Inohara T, Kohsaka S, Yamaji K, Amano T, Fujii K, Oda H, Uemura S, Kadota K, Miyata H, Nakamura M, Investigators JPR. Impact of institutional and operator volume on short-term outcomes of percutaneous coronary intervention: a report from the Japanese Nationwide Registry. JACC Cardiovasc Interv. 2017;10:918–27. https://doi.org/10.1016/j.jcin.2017.02.015.CrossRefPubMed Inohara T, Kohsaka S, Yamaji K, Amano T, Fujii K, Oda H, Uemura S, Kadota K, Miyata H, Nakamura M, Investigators JPR. Impact of institutional and operator volume on short-term outcomes of percutaneous coronary intervention: a report from the Japanese Nationwide Registry. JACC Cardiovasc Interv. 2017;10:918–27. https://​doi.​org/​10.​1016/​j.​jcin.​2017.​02.​015.CrossRefPubMed
9.
17.
Zurück zum Zitat Kaneko H, Itoh H, Yotsumoto H, Kiriyama H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Morita H, Yasunaga H, Komuro I. Characteristics and outcomes of super-elderly patients (aged>=90 years) hospitalized for heart failure—analysis of a nationwide inpatient database-. Circ Rep. 2020;2:393–9.CrossRefPubMedPubMedCentral Kaneko H, Itoh H, Yotsumoto H, Kiriyama H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Morita H, Yasunaga H, Komuro I. Characteristics and outcomes of super-elderly patients (aged>=90 years) hospitalized for heart failure—analysis of a nationwide inpatient database-. Circ Rep. 2020;2:393–9.CrossRefPubMedPubMedCentral
20.
22.
Zurück zum Zitat Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, Paugam-Burtz C, Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A, Mebazaa A. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013;34:742–9. https://doi.org/10.1093/eurheartj/ehs332.CrossRefPubMed Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, Paugam-Burtz C, Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A, Mebazaa A. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013;34:742–9. https://​doi.​org/​10.​1093/​eurheartj/​ehs332.CrossRefPubMed
26.
Zurück zum Zitat Doi SA, Islam N, Sulaiman K, Alsheikh-Ali AA, Singh R, Al-Qahtani A, Asaad N, AlHabib KF, Al-Zakwani I, Al-Jarallah M, AlMahmeed W, Bulbanat B, Bazargani N, Amin H, Al-Motarreb A, AlFaleh H, Panduranga P, Shehab A, Al Suwaidi J, Salam AM. Demystifying Smoker’s paradox: a propensity score-weighted analysis in patients hospitalized with acute heart failure. J Am Heart Assoc. 2019;8:e013056. https://doi.org/10.1161/JAHA.119.013056.CrossRefPubMedPubMedCentral Doi SA, Islam N, Sulaiman K, Alsheikh-Ali AA, Singh R, Al-Qahtani A, Asaad N, AlHabib KF, Al-Zakwani I, Al-Jarallah M, AlMahmeed W, Bulbanat B, Bazargani N, Amin H, Al-Motarreb A, AlFaleh H, Panduranga P, Shehab A, Al Suwaidi J, Salam AM. Demystifying Smoker’s paradox: a propensity score-weighted analysis in patients hospitalized with acute heart failure. J Am Heart Assoc. 2019;8:e013056. https://​doi.​org/​10.​1161/​JAHA.​119.​013056.CrossRefPubMedPubMedCentral
Metadaten
Titel
Impact of hospital volume on clinical outcomes of hospitalized heart failure patients: analysis of a nationwide database including 447,818 patients with heart failure
verfasst von
Hidehiro Kaneko
Hidetaka Itoh
Haruki Yotsumoto
Hiroyuki Kiriyama
Tatsuya Kamon
Katsuhito Fujiu
Kojiro Morita
Nobuaki Michihata
Taisuke Jo
Norifumi Takeda
Hiroyuki Morita
Hideo Yasunaga
Issei Komuro
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2021
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-021-01863-4

Weitere Artikel der Ausgabe 1/2021

BMC Cardiovascular Disorders 1/2021 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.